Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Date publication

juillet 2023

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François , Dr NARDIN Charlée

Tous les auteurs :
Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L, Peuvrel L, Rouanet J, Brunet-Possenti F, Gerard E, Seris A, Jouary T, Saint-Jean M, Puyraveau M, Saiag P, Aubin F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37509227

Résumé

The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature.

Mots clés

anti-CTLA-4, anti-PD1, disease control, immune checkpoint inhibitor, immunotherapy, melanoma, re-induction, rechallenge, response, retreatment, safety

Référence

Cancers (Basel). 2023 07 10;15(14):